Literature DB >> 15747344

Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity?

Thomas M Kessler1, Hansjörg Danuser, Martin Schumacher, Urs E Studer, Fiona C Burkhard.   

Abstract

AIMS: To assess and compare the effect of botulinum A toxin (BTX-A) injections into the detrusor in idiopathic and neurogenic detrusor overactivity resistant to anticholinergic treatment. PATIENTS AND METHODS: In a prospective study, 11 patients with idiopathic and 11 with neurogenic detrusor overactivity resistant to anticholinergic treatment were injected with 300 U of BTX-A (Botox) into the detrusor. Clinical and urodynamic parameters were assessed before and after BTX-A injections.
RESULTS: In idiopathic as well as in neurogenic detrusor overactivity, median daytime frequency decreased significantly from 11 to 4 (P = 0.004) and 12 to 5 (P = 0.001), median nocturia from 3 to 1 (P = 0.004) and 3 to 1 (P = 0.001), and median number of used pads from 5 to 0 (P = 0.001) and 5 to 0 (P = 0.002), respectively. There was a significant increase in median maximum cystometric capacity from 220 to 340 ml (P = 0.001) and 190 to 410 ml (to instead of) (P = 0.001), median bladder compliance from 20 to 55 ml/cm H(2)O (P = 0.001) and 23 to 60 ml/cm H(2)O (P = 0.004) and median post void residual from 10 to 140 ml (P = 0.002) and 30 to 240 ml (P = 0.002), respectively. Median maximum detrusor pressure decreased significantly from 45 to 29 cm H(2)O (P = 0.002) and 40 to 24 cm H(2)O (P = 0.002), and median detrusor pressure at maximum flow rate from 30 to 14 ml/sec (P = 0.001) and 38 to 21 ml/sec (P = 0.016), respectively. Due to post void residuals >150 ml following BTX-A injections, de novo clean intermittent self-catheterization was necessary in nine patients (four with idiopathic and five with neurogenic detrusor overactivity) and in one patient (with idiopathic detrusor overactivity) a suprapubic catheter was placed. The effect of BTX-A injections lasted for a median time of 5 months in both idiopathic and neurogenic detrusor overactivity. There was no significant difference in idiopathic compared to neurogenic detrusor overactivity in regard to clinical and urodynamic parameters assessed before and after BTX-A injections.
CONCLUSIONS: BTX-A injections into the detrusor have a significant and comparable but temporally limited effect in idiopathic and neurogenic detrusor overactivity resistant to anticholinergic treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15747344     DOI: 10.1002/nau.20105

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  29 in total

Review 1.  [Botulinum toxin versus sacral neuromodulation for idiopathic detrusor overactivity].

Authors:  W Leicht; C Hampel; J Thüroff
Journal:  Urologe A       Date:  2012-03       Impact factor: 0.639

2.  Treatment satisfaction and goal attainment with onabotulinumtoxinA in patients with incontinence due to idiopathic OAB.

Authors:  Linda Brubaker; Angelo Gousse; Peter Sand; Catherine Thompson; Vaishali Patel; Jihao Zhou; Brenda Jenkins; Karl-Dietrich Sievert
Journal:  Int Urogynecol J       Date:  2012-01-25       Impact factor: 2.894

Review 3.  [Intravesical treatment of overactive bladder syndrome].

Authors:  A Haferkamp; M Hohenfellner
Journal:  Urologe A       Date:  2006-10       Impact factor: 0.639

Review 4.  [Botulinum toxin for the treatment of neurogenic detrusor hyperactivity. Consensus paper on use for neurogenic bladder dysfunction].

Authors:  K-D Sievert; J Bremer; H Burgdörfer; B Domurath; C Hampel; J Kutzenberger; C Seif; M Stöhrer; B Wefer; J Pannek
Journal:  Urologe A       Date:  2007-03       Impact factor: 0.639

Review 5.  Botulinum toxin treatment for overactive bladder: risk of urinary retention.

Authors:  Ahmed M Shaban; Marcus J Drake
Journal:  Curr Urol Rep       Date:  2008-11       Impact factor: 3.092

6.  Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system.

Authors:  Dirk Dressler
Journal:  J Neurol       Date:  2012-08-10       Impact factor: 4.849

7.  OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales.

Authors:  Nick Freemantle; Kristin Khalaf; Clara Loveman; Sanja Stanisic; Dmitry Gultyaev; Johanna Lister; Marcus Drake
Journal:  Eur J Health Econ       Date:  2015-10-19

8.  Botulinum toxin for the treatment of idiopathic and neurogenic overactive bladder: state of the art.

Authors:  Victor W Nitti
Journal:  Rev Urol       Date:  2006

Review 9.  Medical Management of Neurogenic Bladder for Children and Adults: A Review.

Authors:  Elizabeth Lucas
Journal:  Top Spinal Cord Inj Rehabil       Date:  2019

10.  Biomaterials in urinary incontinence and treatment of their complications.

Authors:  Philippa Sangster; Roland Morley
Journal:  Indian J Urol       Date:  2010-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.